The bispecific antibody drugs targeting PD-L1 and VEGF simultaneously obtained NMPA clinical trial research license
On December 28, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's bispecific antibody drug (Project No.: IMM2510) targeting PD-L1 and VEGF has recently obtained the NMPA clinical trial research license (acceptance No.:CXSL2000290). After IMM01 (CD47) and IMM0306 (CD47xCD20) which are under clinical trial research, this is the third new drug project of ImmuneOnco officially entered the stage of clinical trial research; it also marks the first time that the PD-1/PD-L1 targeted tumor microenvironment targeted drugs for advanced solid tumor treatment arranged by ImmuneOnco have entered the stage of clinical trial research, which is another major milestone of the company's development.
IMM2510 project is a bispecific antibody drug with independent intellectual property rights, which is developed based on the "mAb-Trap" technology platform of ImmuneOnco. It can block the combination of PD-L1 and PD-1 by targeting the immune regulatory target PD-L1, and relieve the immune escape of tumor cells. It can activate NK cells and macrophages through Fc mediated ADCC/ADCP, so as to play a strong role in tumor immunotherapy Over targeting VEGF can inhibit tumor angiogenesis, tumor growth and tumor metastasis, making tumor shrink and soften, and easy to be attacked by immune cells. Preclinical data confirmed that IMM2510 had significant therapeutic effect in a variety of tumor models, and was significantly better than the combination of two single drugs at the same dose.
"I'm very glad that our products have entered into clinical trials one after another. This IMM2510 project has been successfully approved by NMPA clinical trials, which indicates that ImmuneOnco continues to further research and development in the field of bispecific antibody drugs. IMM2510 is a dual targeting PD-L1 and VEGF at the same time. In May this year, FDA approved Roche's PD-L1 antibody (Tecentriq) combined with VEGF antibody (Avastin) for the first-line treatment of advanced liver cancer, which opened a precedent for the first-line immunotherapy of liver cancer. The efficacy of our bispecific antibody in animal tumor model is significantly better than that of the combination of two single drugs, indicating that no matter from the clinical stage IMM2510 will have a great competitive advantage in terms of clinical efficacy and economic burden of patients. We are looking forward to the excellent clinical performance of IMM2510 project. " Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, said: "ImmuneOnco has been committed to the research and development of anti-tumor drugs to create new immune regulatory targets. In addition to IMM01 (CD47), IMM0306 (CD47xCD20) and IMM2510 (PD-L1xVEGF), we also have several other bispecific target specific protein drugs that have shown good development prospects. We will continue to deepen the anti-tumor field, accelerate the pace of research and development, and develop one safe and efficient anti-tumor drug after another, so as to bring good news to the majority of cancer patients.
IMM2510 is an antibody receptor recombinant protein (mAb-Trap) targeting PD-L1 and VEGF at the same time. It is a bispecific antibody drug with independent intellectual property rights of ImmuneOnco. The drug can act on tumor disease targets and regulate the immune system at the same time, and play a strong anti-tumor effect by activating the immune system and inhibiting the growth of tumor cells.
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573